Rain On­col­o­gy's stock dives af­ter tu­mor treat­ment fails a PhI­II tri­al

Rain On­col­o­gy’s treat­ment for ded­if­fer­en­ti­at­ed li­posar­co­ma failed a Phase III clin­i­cal tri­al, rais­ing ques­tions about what’s next for the Bay Area biotech’s lead can­di­date.

On Mon­day, Rain On­col­o­gy un­veiled da­ta from its MANTRA tri­al in­ves­ti­gat­ing milademetan, an oral small mol­e­cule in­hibitor, in pa­tients with ded­if­fer­en­ti­at­ed li­posar­co­ma, a rare type of can­cer that is found in the soft tis­sue. The tri­al did not meet its pri­ma­ry end­point of pro­gres­sion-free sur­vival com­pared to tra­becte­din, the stan­dard of care. John­son & John­son mar­kets Yon­delis, the brand name ver­sion of tra­becte­din.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.